Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03778229 · ClinicalTrials.gov registry record · Phase 2
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
A Phase 2 study of Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 367
- Enrollment target
- 20
- Study locations
NCT03778229 is a Phase 2 study of Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 367 participants, above the 242-participant average among 29 other Carcinoma trials with a reported enrollment target (52% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03778229, a Phase 2 study of Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 367 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
Conditions Studied
Interventions
- DRUG placebo
- DRUG osimertinib
- DRUG savolitinib
Study Locations (20)
Other
- Research Site - Barretos
- Research Site - Curitiba
- Research Site - Goiânia
- Research Site - Porto Alegre
- Research Site - Porto Alegre
- Research Site - Rio de Janeiro
- Research Site - Salvador
- Research Site - São José do Rio Preto
- Research Site - São Paulo
California
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - Sacramento
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
District of Columbia
- Research Site - Washington D.C.
Maryland
- Research Site - Baltimore
Massachusetts
- Research Site - Boston
Minnesota
- Research Site - Rochester
New York
- Research Site - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2019-01-09 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03778229
The ClinicalTrials.gov registry entry for NCT03778229 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 242-participant average among 29 other Carcinoma trials with a reported enrollment target (52% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT03778229 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03778229 about?
NCT03778229 is a clinical study titled "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib". This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
What is the current status of trial NCT03778229?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 367 participants. The study started on 2019-01-09. Estimated completion is 2026-12-31.
What conditions does trial NCT03778229 study?
This clinical trial studies the following conditions: Carcinoma.
What interventions are being tested in trial NCT03778229?
The interventions under investigation include: placebo (DRUG), osimertinib (DRUG), savolitinib (DRUG).
Who is sponsoring clinical trial NCT03778229?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03778229 being conducted?
This trial has 20 study locations across California, District of Columbia, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
RECRUITING · Phase 2
-
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
COMPLETED · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.